Clinical Trials · NCT05801705

Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study

Name: Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

UnknownN/AGonadorelin

Phase: N/A
Recruitment status: Unknown
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Enrollment: 700
Start date: Jun 2023
Locations: 1 site, China
Primary endpoint: disease free survival

View Gonadorelin compound reference